Vinorelbine (Navelbine®): A third-generation vinca alkaloid

Cancer Investigation

Volumn 15, Issue 5, 1997, Pages 475-490

  Budman, Daniel R ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DACTINOMYCIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IFOSFAMIDE; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; NAVELBINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINBLASTINE; VINCA ALKALOID; DRUG DERIVATIVE;

ANIMAL CELL; ANIMAL MODEL; BONE MARROW TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; ESOPHAGUS CARCINOMA; GASTROINTESTINAL TOXICITY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MOUSE; NEUROTOXICITY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; TREATMENT OUTCOME; ANIMAL; BREAST TUMOR; CHEMISTRY; FEMALE; LUNG TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CLINICAL TRIALS; FEMALE; HUMANS; LUNG NEOPLASMS; VINBLASTINE;

EID: 0030610102     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909709047587     Document Type: Review

References (140)

1. Noble RL, Beer CT, Cutis JH: Further biological activities of vincaleukoblastine - An alkaloid isolated from Vinca rosea (L). Biochem Pharmacol 1:347-348, 1858.
2. Frei E, Franzino A, Schneider BL, et al: Clinical studies of vinblastine. Cancer Chemother Rep 12:125-129, 1961.
3. Budman DR: New vinca alkaloids and related compounds. Semin Oncol 19:639-645, 1992.
4. Mangeney P, Andriamialisoa R, Lallemand JY, et al: 5′Noranhydrovinblastine. Prototype of a new class of vinblastine derivatives. Tetrahedron 35:2175-2179, 1979.
5. Fellous A, Ohayon R, Vacassin T, et al: Biochemical effects of Navelbine on tubulin and associated proteins. Semin Oncol 16(Suppl 4):9-14, 1989.
6. Binet S, Fellous A, Lataste H, et al: In situ analysis of Navelbine on various types of microtubules using immunofluorescence. Semin Oncol 16(Suppl 4):5-8, 1989.
7. Etievant C, Pauwels O, Kiss R: Digital cell image analysis of verapamil-induced effects in chemosensitive and chemoresistant neoplastic cell lines. J Cancer Res Clin Oncol 120:76, 1993.
8. Zhou XJ, Placidi M, Rahmani R: Uptake and metabolism of vinca alkaloids by freshly isolated human hepatocytes in suspension. Anticancer Res 14:1017-1022, 1994.
9. Wargin WA, Sol Lucas V: The clinical pharmacokinetics of vinorelbine (Navelbine). Semin Oncol 21(Suppl 10):21-27, 1994.
10. Zhou-Pan XR, Seree E, Zhou XJ, et al: Involvement of human liver cytochrome P450 3A in vinblastine metabolism: Drug interactions. Cancer Res 53:5121-5126, 1993.
11. Tobe SW, Siu LL, Jamal SA, et al: Vinblastine and erythromycin: An unrecognized serious drug interaction. Cancer Chemother Pharmacol 35:188-190, 1995.
12. Rajaonarison JF, Lacarelle B, Catalin J, et al: Effect of anticancer drugs on the glucuronidation of 3′-azido-3′-deoxythymidine in human liver microsomes. Drug Metal. Dispos 21:823-829, 1993.
13. Knick VC, Miller CG: In vivo derivation of a murine P 388 leukemia subline resistant to 5′nor-anhydrovinblastine (Navelbine) and its cross-resistance profile. Proc Am Assoc Cancer Res 33:462, 1992.
14. Mazzoni A, Trave F, Russo P, et al: Generation and characterization of a low-degree drug resistant human tumor cell line. Oncology 47:488 -494, 1990.
15. Debal V, Allam N, Morjani H, et al: Characterization of a Navelbine-resistant bladder carcinoma cell line cross-resistant to taxoids. Br J Cancer 70:1118-1125, 1994.
16. Photiou A, Sheikh MN, Bafaloukos D, et al: Antiproliferative activity of vinorelbine (Navelbine) against six human melanoma cell lines. J Cancer Res Clin Oncol 118:249-254, 1992.
17. Bums III HA, Fields S: Summary of data from in vitro and phase I vinorelbine (Navelbine) studies. Semin Oncol 5:(Suppl 10):14-20, 1994.
18. Ashizawa T, Miyoshi K, Asada M, et al: Antitumor activity of Navelbine (vinrorelbine ditratrate), a new vinca alkaloid analog. Gan to Kagaku Ryoho 20:59-66, 1993.
19. Ashizawa T, Asada M, Kobayashi E, et al: Combination effect of Navelbine (vinorelbine ditartrate) with cisplatin against murine P388 leukemia and human lung carcinoma xenografts in mice. Anti-cancer Drugs 4:577-583, 1993.
20. Bissery MC, Vrignaud P, Bayssas M, et al: Preclinical in vivo activity of docetaxel containing combinations. Proc Am Soc Clin Oncol 14:489, 1995.
21. Adams DJ: Synergy of Navelbine-taxol combination treatment in two human breast cancer cell lines. Proc Am Assoc Cancer Res 35:327, 1994.
22. Knick VC, Eberwein DJ, Miller CG: Preclinical activity of Navelbine and taxol drug combinations. Proc Am Assoc Cancer Res 35:327, 1994.
23. Dine T, Luyckx M, Cazin JC, et al: Stability and compatibility studies of vinblastine, vincristine, vindesine and vinorelbine with PVC infusion bags. Int J Pharmaceut 77:279-285, 1991.
24. American Society of Hospital Pharmacists: ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm 47:1033-1049, 1990.
25. Harrison BR: Safe handling of cytotoxic drugs: a review. In: The Chemotherapy Source Book, edited by MC Perry, Baltimore, Williams & Wilkins, 1992, pp 799-832.
26. Trissel LA, Martinez JF: Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tratrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 51:495-497, 1994.
27. Investigator's Brochure. Burroughs-Wellcome Company, on file with the U.S. Federal Food and Drug Administration.
28. Krikorian A, Breillout F: Vinorelbine (Navelbine). A new semisynthetic vinca alkaloid. Onkologie 14:7-12, 1991.
29. Rahmani R, Gueritte F, Martin M, et al: Comparative pharmacokinetics of antitumor vinca alkaloids: Intravenous bolus injections of Navelbine and related alkaloids to cancer patients and rats. Cancer Chemother Pharmacol 16:223-228, 1986.
30. Leveque D, Merle-Melet M, Bresler L, et al: Biliary elimination and pharmacokinetics of vinorelbine in micropigs. Cancer Chemother Pharmacol 32:487-490, 1993.
31. Marquet P, Lachatre G, Debord J, et al: Pharmacokinetics of vinorelbine in man. Eur J Clin Pharmacol 42:545-547, 1992.
32. Rahmani R, Bruno R, Iliadis A, et al: Clinical pharmacokinetics of the antitumor drug Navelbine (5′-noranhydrovinblastine). Cancer Res 47:5796-5799, 1987.
33. Jehl F, Quoix H, Leseque D, et al: Pharmacokinetic and preliminary metabolic fate of Navelbine in humans as determined by high performance liquid Chromatography. Cancer Res 51:2073-2076, 1991.
34. 3H-Navelbine in patients: Comparative pharmacokinetics using radioactive and radioimmunologic determination methods. Anti-cancer Drugs 2:405-410, 1991.
35. Zhou XJ, Bore P, Monjanel S, et al: Pharmacokinetics of Navelbine after oral administration in cancer patients. Cancer Chemother Pharmacol 29:66-70, 1992.
36. Robieux I, Sorio R, Borsatti E, et al: Pharmacokinetics of vinorelbine in patients with liver metastases. Clin Pharmacol Ther 59:32-40, 1996.
37. Madden T, Bleyer A, Hohneker J, et al: The pharmacokinetics of vinorelbine (Navelbine, NVB) in pediatric cancer patients. Proc Am Soc Clin Oncol 14:168, 1995.
38. Rowinsky EK, Noe DA, Trump DL, et al: Pharmacokinetic, bioavailabilily, and feasibility study of oral vinorelbine in patients with solid tumors. J Clin Oncol 12:1754-1763, 1994.
39. Leveque D, Jehl F, Quoix E, et al: Clinical pharmacokinetics of vinorelbine alone and combined with cisplatin. J Clin Pharmacol 32:1096-1098, 1992.
40. Pinedo HM: Vinorelbine: A horse of a different color? J Clin Oncol 12:1745-1746, 1994.
41. Mathe G, Reizenstein P: Phase I pharmacologic study of a new vinca-alkaloid: Navelbine. Cancer Lett 27:285-293, 1985.
42. Hohneker J: A summary of vinorelbine (Navelbine) safely data from North American clinical trials. Semin Oncol 21(Suppl 10):42-47, 1994.
43. Le Chevalie T, Brisgand D, Douillard J-Y, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 12:360-367, 1994.
44. Khayat D, Covelli A, Variol P, et al: Phase I and pharmacologic study of intravenous (i.v.) vinorelbine (VRL) in patients (PTS) with solid tumors. Proc Am Soc Clin Oncol 14:469, 1995.
45. Brosio C, Cinat G, Mickiewicz E, et al: Granulocytic colony stimulating factors (GCSF) support in weekly chemotherapy (CT) with vinorelbine (NVB). Proc Am Soc Clin Oncol 12:144, 1993.
46. Cinat A, Brosio C, Mickiewica E, et al: Filgrastim (G-CSF) support in weekly chemotherapy with vinorelbine (VNB). Proc Am Soc Clin Oncol 14:261, 1995.
47. Crawford J, O'Rourke MA, Herndon J, et al: Sequential trials of vinorelbine (Navelbine, NVB) with carboplatin in patients with advanced non-small cell lung cancer (NSCLC). Proc. Am Soc Clin Oncol 14:376, 1995.
48. Toussaint C, Izzo J, Spielmann M, et al: Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer. J Clin Oncol 12:2102-2112, 1994.
49. Bowen K, Burris H, Rodriguez G, et al: A phase I trial of chronic oral Navelbine administration. Proc Am Assoc Cancer Res 35:519, 1992.
50. Budman DR, Schulman P, Marks M, et al: Phase I Vinzolidine. Cancer Treat Rep 68:979-982, 1983.
51. Cecchi R, Tuci F, Giomi A, et al: Supravenous hyperpigmentation induced by vinorelbine. Dermatology 188:244, 1994.
52. Lozano M, Muro H, Triguboff E, et al: A randomized trial for effective prevention of navelbine (NVB) related phlebitis. Proc Am Soc Clin Oncol 14:535, 1995.
53. Cvitkovic E, Izzo J: The current and future place of vinorelbine in cancer therapy. Drugs 44(Suppl 4):36-45, 1992.
54. Yokoyama A, Furuse K, Niitani H, et al: Multi-institutional phase II study of Navelbine (vinorelbine) in non-small cell lung cancer. Proc Am Soc Clin Oncol 11:287, 1992.
55. Depierre A, Lemarie E, Dabouis G, et al: A phase II sludy of Navelbine (vinorelbine) in the treatment of non-small cell lung cancer. Am J Clin Oncol 14:115-119, 1991.
56. Kusunoki Y, Furuse K, Yamori S, et al: Randomized phase II study of vinorelbine (VRB) vs. vindesine (VDS) in previously untreated non-small cell lung cancer (NSCLC): Final results. Proc Am Soc Clin Oncol 14:353, 1995.
57. Berthaud P, Le Chevalir T, Ruffie P, et al: Phase I-II study of vinorelbine (Nacelbine) plus cisplatin in advanced non-small cell lung cancer. Eur J Cancer 28:1863-1865, 1992.
58. Balbiani L, Coppola F, Blajman C, et al: Navelbine (NVB) vs NVB plus cisplatin (P) in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 12:352, 1993.
59. Depierre A, Chastang C, Quoix E, et al: Vinorelbine versus venorelbine plus cisplatin in advanced non-small cell lung cancer: A randomized trial. Ann Oncol 5:37-42, 1994.
60. Lorusso V, Pezzella G, Catino AM, et al: Results of a clinical multicentric randomized phase II study of non-small cell lung cancer treated with vinorelbine-cisplatin versus vinorelbine alone. Int J Oncol 6:65-68, 1995.
61. Jacoulet P, Dubiez A, Depoerre A, et al: One-week versus 3-weeks intervals in the administration of cisplatine in combination with vinorelbine: A randomized study in non-small-cell cancer (NSCLC). Proc Am Soc Clin Oncol 11:301, 1992.
62. Perol M, Guerin JC, Kleisbauer JP, et al: Multicenter randomized trial comparing cisplatin-mitomycin-vindesine vs cisplatin-mitomycin-Navelbine in advanced non small cell lung cancer (NSCLC). J Int Assoc Study Lung Cancer 11:114, 1994.
63. O'Rourke M, Crawford J, Schiller J, et al: Survival advantage for patients with stage IV NSCLC treated with single agent Navelbine in a randomized controlled trial. Proc Am Soc Clin Oncol 12:343, 1993.
64. Santomaggio C, Righi R, Tucci E, et al: Carboplatin (C) and vinorelbine (V) in metastatic (M) nonsmall cell lung cancer (NSCLC). Preliminary results, J Int Assoc Study Lung Cancer 11(Suppl 1):125, 1994.
65. Crawford J, O'Rourke MA: Vinorelbine (Navelbine)/carboplatin combination therapy: Dose intensification with granulocyte colony-stimulating factor. Semin Oncol 21(Suppl 10):73-78, 1994.
66. Comella P, Casaretti R, Daponte A, et al: Combination of vinorelbine, cisplatin, and etoposide in advanced non-small cell lung carcinoma: A pilot study. J Chemother 6:67-71, 1994.
67. Jacoulet P, Depierre A, Gamier G, et al: Study of combined Navelbine-cisplatin-VP-16 in the treatment of non small cell lung cancer. In: Navelbine (Vinorelbine): Update and New Trends, edited by P Solal-Celigny, Paris, John Libby Eurotex, 1991, pp 171-177.
68. Carles P, Quoix E, Guerin J-C, et al: Presentation of Navelbine combinations in the treatment of non small cell lung cancer. In: Navelbine (Vinorelbine): Update and New Trends, edited by P Solal-Celigny, Paris, John Libbey Eurotex, 1991, pp 137-140.
69. Gridelli C, De Placido S, Pepe R, et al: Phase I study of epirubicin (edx) plus Vinorelbine (vnr) with or without G-CSF in advanced non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 12:342, 1993.
70. Gridelli C, Rosi A. Plazzolo G, et al: Mitomycin C, etoposide and Vinorelbine (MEV H) in the treatment of metastatic stage IV non small cell lung cancer. Tumori 80:128-130, 1994.
71. Comella P, Frasci G, De Cataldis G, et al: Vinorelbine (VNR) combined to cisplatin/carboplatin (CBDCA) and atoposide (VP-16) in advanced NSCLC. Preliminary analysis of a three arm phase III randomized trial. Proc Am Soc Clin Oncol 14:384, 1995.
72. Souquet PJ, Fournel P, Lombard-Bohas CH, et al: Cisplatin (CDDP), ifospfamide (IFM) with various dosages of vinorelbine (NVB) in non-resectable non-small cell lung cancer. Proc Am Soc Clin Oncol 14:367, 1995.
73. Poudenx M, Otto J, Ferrero JM, et al: Vinorelbine (VNR), ifosfamide (IFX), and cisplatin (CDDP) in non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 14:366, 1995.
74. Barone C, Pozzo C, Cassano A, et al: Phase II study of vinorelbine, cisplatin, and ifosfamide combination for advanced non small cell lung cancerpreliminary results. Proc Am Soc Clin Oncol 14:369, 1995.
75. Hoffman P, Drinkard L, Masters G, et al: Ifosfamide plus Navelbine: A phase I study in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 14:358, 1995.
76. Canobbio L, Boccardo F, Pastorino G, et al: Phase-II study of Navelbine in advanced breast cancer. Semin Oncol 16(Suppl 4):33-36, 1989.
77. de Cremoux H, Monnet I, Azli N, et al: Fluorouracil (FU)/leucovorin (AF)/vinorelbine (VNB)/cisplatin (p) in non small cell lung cancer (NSCLC): A phase II study. Proc Am Soc Clin Oncol 11:303, 1992.
78. Tredaniel J, Dieras V, Ferme C, et al: Alternative to cisplatin: 5FU-Navelbine combination. In: Navelbine (Vinorelbine): Update and New Trends, edited by P Solal-Celigny, Paris, John Libbey Eurotex, 1991, pp 163-169.
79. Masters G, Drinkard L, Hoffman P, et al: A phase I study of concomitant chemoradiotherapy with cisplatin (CDDP) and navelbine (NVB) for advanced malignancies of the chest. Proc Am Soc Clin Oncol 14:378, 1995.
80. Viallel J, Rosseau P, Souhami L, et al: A phase I/II trial of neoadjuvant chemotherapy (CT) with cisplatin and vinorelbine (Navelbine) followed by accelerated thoracic irradiation (TRT) in inoperable non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 14:337, 1995.
81. Jassem J, Karnicka-Mlodkowska H, van Pottelsberghe CH, et al: Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. Eur J Cancer 29A:1720-1722, 1993.
82. Furuse K, Kawahara M, Fukuoka M, et al: Early phase II study of vinorelbine (VNR) in small cell lung cancer. J Int Assoc Study Lung Cancer 11(Suppl 1):107, 1994.
83. Depierre A, Le Chevalier T, Quoix E, et al: Phase II study of navelbine (NVB) in small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 14:348, 1995.
84. Tummarello D, Graziano F, Giordani P: A phase II study of vinorelbine (VNB) in small cell lung cancer (SCLC) patients (PTS) unsuitable for standard chemotherapy (CHT). Proc Am Soc Clin Oncol 14:369, 1995.
85. Budman DR: Investigational agents. In: The Chemotherapy Sourcebook, edited by MC Perry, Baltimore, Williams & Wilkins., 1992, p 462.
86. Boccardo F, Canobbio L, Pastorino G, et al: Phase II study of Navelbine (nvb) in advanced breast cancer. Invest New drugs 7:426, 1989.
87. Degardin M, Bonneterre J, Hecquel B, et al: Vinorelbine (Navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 5:423-426, 1994.
88. Romero A, Rabinovich MG, Vallejo CT, et al: Vinorelbine as first-line chemotherapy for metastatic breast cancer. J Clin Oncol 12:336-341, 1994.
89. Marty M, Extra JM, Dieras V, et al: A review of the antitumor activity of vinorelbine in breast cancer. Drugs 44(Suppl 4):29-35, 1992.
90. Twelves CJ, Dobbs NA, Curnow A, et al: A phase II, multicentre, UK study of vinorelbine in advanced breast cancer. Br J Cancer 70:990-993, 1994.
91. Bruno S, Puerto VL, Mickiewicz E, et al: Phase II trial of weekly i.v. vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. The Latin-American experience. Am J Clin Oncol 18:392-396, 1995.
92. Vogel C, O'Rourke M, Weber B, et al: The safety of IV Navelbine in elderly patients with advanced breast cancer (ABC). Presented at the 5th International Congress on Anti-Cancer Chemotherapy, 1995.
93. Winer E, O'Rourke M, Vogel C, et al: A US multicenter phase II trial of oral Navelbine in elderly women with advanced breast cancer. Breast Cancer Res Treat 27:136, 1993.
94. Fumoleau P, Delgado FM, Delozier T, et al: Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 11:1245-1252, 1993.
95. Livingston RB, Ellis GK, Williams MA: Weekly vinorelbine (Navelbine, NVB) + G-CSF in taxol-refractory metastatic breast cancer (MBC); a phase I-II study. Proc Am Soc Clin Oncol 14:110, 1995.
96. Terzoli E, Nistico C, Ranuzzi M, et al: Weekly vinorelbine (V) plus G-CSF in previously treated patients with advanced breast cancer. Breast Cancer Res Treat 37(Suppl):236a, 1996.
97. Pace A, Terzoli E, Bove L, et al: Vinorelbine neurotoxicity: Clinical and neurophysiological findings. 5th International Congress on Anti-cancer Chemotherapy 1995, p 221.
98. Jones S, Winer E, Vogel C, et al: A multicenter randomized trial of iv Navelbine vs iv alkeran in patients with anthracycline refractory advanced breast cancer. Proc Am Soc Clin Oncol 13:103, 1994.
99. Ray-Coquard I, Blay JY, Bachelot T, et al: Continuous infusion of vinorelbine (VNB) and bolus cisplatinum (CDDP) (CIVIC Regimen). An efficient regimen in hormoresistant metastatic breast cancers (M BC) after failure of anthracycline and/or paclitaxel. Proc Am Soc Clin Oncol 14:137, 1995.
100. Hochster H, Vogel C, Blumenreich M, et al: A multicenter phase II study of Navelbine (NVB) and doxorubicin as first line chemotherapy of metastatic breast cancer. Proc Am Soc Clin Oncol 13:100, 1994.
101. Spielmann, M, Dorval T, Turpin F, et al: Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer. J Clin Oncol 12:1764-1770, 1994.
102. Blajman C, Balbiani L, Block J, et al: Navelbine (N) plus adriamycin (A) vs FAC in advanced breast cancer. Proc Am Soc Clin Oncol 12:92, 1993.
103. Chadjaa M, Izzo J, May-Levin F, et al: Preliminary data on 4′epiadriamycine (epi)-vinorelbine (VNB): A new active combination in advanced breast cancer (ABC). Proc Am Soc Clin Oncol 12:88, 1993.
104. Terzoli E, Nistico C, Ranuzzi M, et al: Weekly epirubicin plus vinorelbine in advanced breast cancer: Preliminary results. Proc Am Soc Clin Oncol 14:120, 1995.
105. Van Praagh I, Martineau N, Cure H, et al: Efficacy of a chemotherapy regimen combining vinorelbine, epirubicine and methotrexate (VEM) in locally advanced and metastatic breast cancer. Proc Am Soc Clin Oncol 12:95, 1993.
106. Meriggi F, Zaniboni A, Arcangeli G, et al: VELF: An active outpatient regimen for aggressive metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 13:91, 1994.
107. Dieras V, Pierga JY, Extra JM, et al: Results of a combination of Navelbine (NVB) and fluorouracil (FU) in advanced breast cancer (ABC) with a group sequential design (GSD). Ann Oncol 3(Suppl 5):46, 1992.
108. Leone B, Vallejo C, Romero A, et al: Ifosfamide (IFX) and vinorelbine (VNB) as first-line chemotherapy (FLC) for metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 14:122, 1995.
109. Scheithauer W, Kornek G, Haider K, et al: Effective second line chemotherapy of advanced breast cancer with navelbine and mitomycin C. Breast Cancer Res Treat 26:49-53, 1993.
110. Cole JT, Gralla RJ, Kardinal CG: Navelbine and mitomycin C: Combination therapy in advanced breast cancer. 17th Annual San Antonio Breast Cancer Symposium, 1995.
111. Ferrero JM, Wendling JL, Hock M, et al: Mitoxanthrone (mtz) - vinorelbine (vnr) as first line chemotherapy (ct) in metastatic breast cancer (MBC): A pilot study. Proc Am Soc Clin Oncol 12:108, 1993.
112. Kayitalire L, Spielmann M, Brain E, et al: Salvage chemotherapy (CT) with combination of mitoxanthrone (MTZ) and vinorelbine (VNR) in resistant to anthracyclines advanced breast cancer. Proc Am Soc Clin Oncol 12:90, 1993.
113. Colleoni M, Gaion F, Sgarbossa P, et al: Phase II study of miloxanthrone, fluorouracil plus folates and vinorelbine in patients with previously treated advanced breast cancer (ABC). 5th International Conference on Anlicancer Chemotherapy, 1995, p 112.
114. Botto HG, Galmarini F, Galvez C: Mitoxanthrone (M), ifosfamide (I), vinorelbine (V), (MIV) and GM-CSF in refractory metastatic breast cancer (RMBC). Proc Am Soc Clin Oncol 13:85, 1994.
115. Terzoli E, Nistico C, Ranuzzi M, et al: Weekly epirubicin (E) plus vinorelbine (V) and G-CSF in advanced breast cancer (ABC): An active treatment. Breast Cancer Res Treat 37 (Suppl):113a, 1996.
116. 116: Budman DR, Calabro A, Stiel L, et al: In vitro studies of paclitaxel in combination with either etoposide or vinorelbine: sequence dependent effects causing synergism or antagonism. Proc Am Assoc Cancer Res 37:2493a, 1996.
117. Chang AY, Garrow GC: Pilot study of vinorelbine (Navelbine) and paclitaxel (Taxol) in patients with refractory breast cancer and lung cancer. Semin Oncol 22:6670, 1995.
118. Fazeny B, Zifko U, Meryn S, et al: Navelbine-induced neurotoxicity in patients with advanced breast cancer prelreated with paclitaxel. Proc Am Soc Clin Oncol 13:57, 1994.
119. Vogel C, Hochster H, Blumenreich M, et al: A US multicenter phase II study of IV Navelbine (NVB) and 5-fluorouracil (5FU) as first line treatment of patients with advanced breast cancer (ABC). Proc Am Soc Clin Oncol 14:91, 1995.
120. Conroy T, Etienne PL, Adenis A, et al: Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. J Clin Oncol 14:164-170, 1996.
121. George MJ, Heron JF, Kerbrat P, et al: Navelbine in advanced ovarian epithelial cancer: A study of the French oncology centers. Semin Oncol 16(Suppl 4):30-32, 1989.
122. Pinon G, Pinel MC, Goudier MJ, et al: Study of vinorelbine (V) combined with hexamethylmetamine (H) (Combination V-H) in adenocarcinoma of the ovary: Results of a phase MIA trial, NHO88, of ARTC Ovarian Group. Bull Cancer (Paris) 78:1119-1131, 1991.
123. Canobbio L, Boccardo F, Guarneri D, et al: Phase II study of Navelbine in advanced renal cancer. Eur J Cancer 27:804-805, 1991.
124. Wilding G, Kirkwood J, Clamon G, et al: Phase II trial of Navelbine in metastatic renal cancer. Proc Am Soc Clin Oncol 12:253, 1993.
125. Bnchekroun S, Chouffai Z, Harif M, et al: Clinical study of Navelbine activity in Hodgkin's disease. Phase II study. In: Navelbine (Vinorelbine): Update and New Trends, edited by P Solal-Celigny, Paris, John Libbey Eurotex, 1991, pp 261-264.
126. Bruno S, Savignano R, Corrado C, et al: Vinorelbine (NVB): A new vinca alkaloid active in refractory/relapsed lymphomas. A phase II study. Proc Am Soc Clin Oncol 13:382, 1994.
127. Romanini A, Surbone A, Ricci S, et al: Phase II study of continuous infusion of vinorelbine (CIV) in patients with locally pretreated advanced head and neck career. Proc Am Assoc Cancer Res 34:205, 1993.
128. Gebbia V, Testa A, Valenza R, et al: A pilot study of vinorelbine on a weekly schedule in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer 29A:1358-1359, 1993.
129. Gebbia V, Testa A, Valenza R, et al: Vinorelbine plus cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell head and neck carcinoma. Proc Am Soc Clin Oncol 12:283, 1993.
130. Fields S, Burris H III, Wilding G, et al: Evaluating the role of Navelbine in hormone-refractory prostate cancer (HRPC): A clinical benefit model. Proc Am Soc Clin Orcol 13:235, 1994.
131. Kris MG, Gralla RJ, Kalman LA, et al: Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non-small cell lung cancer, with an analysis of methods of response assessment. Cancer Treat Rep 69:387-395, 1985.
132. Carrato A, Rosell R, Artal A, et al: Preliminary results of a phase II trial of biweekly vinorelbine as a single agent in nonsmall cell lung cancer (NSCLC). Spanish Cancer Group. Proc Am Soc Clin Oncol 13:338, 1994.
133. Crivellari D, Versonesi A, Sacco C, et al: Phase II study of vinorelbine (V) in 50 patients with non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 13:355, 1994.
134. Fernandez O, Bruno S, Mickiewicz E, et al: Randomized prospective comparison of Navelbine (NVB) and cisplatin vs. Navelbine alone in patients with inoperable non small cell lung cancer. J Cancer Res Clin Oncol 116(Suppl 1):111, 1990.
135. Kusunoki Y, Furuse Y, Yamori S, et al: Randomized phase II study of vinorelbine (VNR) vs. vindesine (VD) in previously untreated non-small cell lung cancer (NSCLC). J Int Assoc Study Lung Cancer 11(Suppl 1):113, 1994.
136. Lonardi F, Pavanato G, Jirillo A, et al: Vinorelbine (VNB) as single agent chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 13:338, 1994.
137. Masotti A, Zannini G, Poggi R, et al: Vinorelbine monochemotherapy in non-small cell lung cancer: Experience in patients wilh low performance status. Monaldi Arch Chest Dis 49:197-200, 1994.
138. Santoro A, Maiorino L, Santoro M: Second-line therapy with vinorelbine in the weekly monotherapy for the treatment of advanced non small cell lung cancer. J Int Assoc Study Lung Cancer 11(Suppl 1a):113, 1994.
139. Vokes EE, Rosenberg R, Jahnazeb M, et al: Multicenter study of oral Navelbine (NVB) in previously untreated stage IV non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 12:336, 1993.
140. Adenis A, Vanlemmens L, Fournier CH, et al: Mitoxanthrone (DHAD) and vinorelbine (VNR) as a primary treatment of locoregional breast cancer (BC). Proc Am Soc Clin Oncol 14:138, 1995.